tbuckley/cabot-search huggingface dataset:
494P Landscape of MET activating alterations (METa) in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and the Middle East (AME)
Authors: B.C. Cho, N. Peled, B-C. Ahn, S. Dawood, C-M. Tsai, S. Khandelwal, N. Sandhir, S. Olsen
Journal: Annals of Oncology (2024)
427P Direct medical costs of nasopharyngeal carcinoma in Indonesia: A healthcare payer perspective
Authors: C. Irawan, E. Kristin, S.H. Hutajulu, Y.A. Dewi, G.B. Prajogi, L.R. Andalucia, D. Hendrawan, S.I. Jaya, R. Ramadani, S.H. Yeo, S. Dhawan, J. Ng
Journal: Annals of Oncology (2024)
529MO Cell-free concentrated ascites reinfusion therapy (CART) followed by chemotherapy for the patients with cancerous ascites: A case control study from a single institution in Japan
Authors: M. Hosoda, S. Marshall, H. Imada, S. Goto, Y. Okabe, A. Kimura, H. Ohno, T. Ogawa
Journal: Annals of Oncology (2024)
452P Characteristics and treatment patterns of patients diagnosed with nasopharyngeal carcinoma in Indonesia: A descriptive study using the National Health Insurance database
Authors: S.H. Hutajulu, E. Kristin, G.B. Prajogi, Y.A. Dewi, C. Irawan, L.R. Andalucia, D. Hendrawan, S.I. Jaya, R. Ramadani, S.H. Yeo, S. Dhawan, J. Ng
Journal: Annals of Oncology (2024)
422P Claudin-1 (CLDN1) expression in nasopharyngeal carcinoma (NPC): Association with immune exclusion and implications for immune checkpoint inhibitor (ICI) therapy
Authors: E.L.L. Yeo, J. Neo, E. Ong, W.M. Chow, K.M. Tan, J. Tan, J.P.S. Yeong, T.K.H. Lim, J.S.G. Hwang, Q.S. Ng, Y.L. Soong, M-K. Ang, S.H. Tan, M.L.K. Chua, D.W-T. Lim
Journal: Annals of Oncology (2024)
417P Final and exploratory results of a phase I trial evaluating novel radioenhancer NBTXR3 activated by radiotherapy in cisplatin-ineligible LA HNSCC patients
Authors: C. Le Tourneau, X. Liem, T.V. Nguyen, S. El Bedoui, S. Salas, M. Plana Serrahima, X. Mirabel, S. Wong Hee Kam, L. Finzi, A. Debard, O.I. Vivar, P. Gorphe, J. Thariat, M. Lesnik, F. Helfferich, A. Herczeg, Z. Papai, J. Fijuth, Z. Takacsi-Nagy
Journal: Annals of Oncology (2024)
483MO RNA-based multiplex polymerase chain reaction and sequencing to detect fusion genes in melanoma
Authors: T. Hida, M. Idogawa, J. Kato, K. Horimoto, S. Sato, Y. Kiniwa, S. Sugita, M. Okura, R. Okuyama, T. Tokino, H. Uhara
Journal: Annals of Oncology (2024)
426P Trop-2 and Nectin-4 expression and their relationship with tumor immune microenvironment in salivary gland cancer
Authors: Y. Nagatani, N. Kiyota, Y. Imamura, T. Koyama, S. Kimbara, Y. Funakoshi, T. Itoh, H. Fujiwara, H. Shimoda, M. Teshima, K-I. Nibu, K. Sakai, K. Nishio, D. Ikarashi, S. Kitano, H. Minami
Journal: Annals of Oncology (2024)
404O A phase III prospective randomised trial of two- weekly TPF(Taxane/Platinum/5FU) vs three weekly TPF as induction chemotherapy in locally advanced squamous cell carcinoma of head and neck: A preliminary analysis
Authors: A. Gupta, L.A. Jacob, S.B. Mallekavu Chikkadasappa, K.N. Lokesh, A.H. Rudresha, R.K. Lakkavalli Krishnappa, S.C. Saldanha
Journal: Annals of Oncology (2024)
592TiP The safety and efficacy of acupuncture in breast cancer survivors with post-mastectomy pain syndrome, a single-arm exploratory study (ABC-1 study)
Authors: N. Kawasaki, H. Ishiki, N. Matsubara, T. Ikegami, A. Ishikawa, R. Nishimura, S. Arakawa, T. Uchida, Y. Nameki, A. Takahashi, Y. Horiguchi, A. Ogawa, C. Watase, T. Murata, S. Shiino, S. Takayama, A. Suto, H. Matsuoka, E. Satomi
Journal: Annals of Oncology (2024)
408MO Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma
Authors: H. Cheng, J. Chen, G. Jia, Y-J. Liang, Y. Li, Y. Chen, J.Y. Lin, P. Wang, Q.Y. Chen, L.Q. Tang, H. Mai, L. Liu
Journal: Annals of Oncology (2024)
463MO Active treatment in final weeks of life: Importance of palliative care in advanced non-small-cell lung cancer
Authors: L. Posado-Domínguez, A. Olivares Hernandez, L. Bellido Hernández, P. Díaz Sánchez, C.M. Sanz Blanco, S.L. Espinal Matos, J. Roldan Ruiz, L. Figuero Pérez, L.C. Felix, M.D.C. Garijo Martínez, E. Fonseca Sánchez, E. del Barco Morillo
Journal: Annals of Oncology (2024)
LBA4 A randomized controlled trial to relieve distress of chemotherapy-induced peripheral neuropathy by magnetic field: SMILE study
Authors: E. Kubo, E. Satomi, T. Mukohara, N. Fuse, M. Wakabayashi, Y. Tsukada, H. Ishiki, S. Takayama, Y. Kanemitsu, I. Kishita, K. Kobayashi, C. Kurihara, N. Hirano, T. Ikeno, T. Miura, A. Sato
Journal: Annals of Oncology (2024)
515P Implementation of HRD testing in Vietnam: Lesson learnt from Vinmec Hitech Center
Authors: H.T.T. Tran, T.H. Nguyen, D-M. Vu, N.P. Dinh, Q.V. Hoang, H.D. Do, T.D. Nguyen, A.H.M. Vo, X.H. Nguyen
Journal: Annals of Oncology (2024)
411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial
Authors: C. Le Tourneau, J. Fayette, C. Even, A.G. Sacco, A. Daste, I. Braña, C. van Herpen, T. Mazard, S. Henry, M. Saerens, A.K. Joe, E.J. Pennella, Y-M. Shen, K. Bol, L. Jain, M. Magin Ferrer, R. de Leeuw, A. Hollebecque
Journal: Annals of Oncology (2024)
437P Real-world efficacy of induction chemotherapy followed by chemoradiotherapy compared to concurrent chemoradiation therapy in patients with very advanced head and neck squamous cell cancer
Authors: O. Stativko, I. Pokataev, M. Nosova, E. Sabitov, E. Tsareva, O. Kuchevskaya, E. Kuzmina, M.A. Lyadova, T. Antonova, M. Dolov, A. Tedeeva, S. Kravtsov, S. Parts, V.N. Galkin
Journal: Annals of Oncology (2024)
532P Feasibility of hydromorphone PCA 10-day simple mode home management of patients in severe pain or pain crisis: A prospective multicenter study
Authors: P. Lu, Z. Min, Y. Ji, Z. Kelei, C. Li, G. Zhang, P. Wang, Y. Han, J. He, W. Chang, H. Yin, Y. Yao, G. Chen, Y. Cui, Y. Dong, H. Dong, Q. Zhang, D. Tang, B. Li
Journal: Annals of Oncology (2024)
416P A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with chemotherapy for the treatment of anti-PD-1 resistant, recurrent, or metastatic nasopharyngeal carcinoma (R/M NPC)
Authors: L. Wen, Z. Zhang, J. Huang, X. Hong, B. Wu, Q. Ding, G. Peng, K. Yang
Journal: Annals of Oncology (2024)
433P Investigating the effectiveness and safety of the economically viable and well-tolerated capecitabine and cyclophosphamide drug combination in advanced head and neck cancer: A prospective study in India
Authors: K. Baruah, L.K. R., L.A. Jacob, S. Babu Mc, K.N. Lokesh, A.H. Rudresha, S.C. Saldanha
Journal: Annals of Oncology (2024)
471P “A lot happens after best supportive care”: Unbottling the counter transference of health-related suffering in a community cancer palliative care setting – A case study method
Authors: V. Viswanath, V.P. Ravuru, S. Ketireddi, A. Karim, M. Priyanshu, A. Khan, S.K. Duvvada, B. Geddam, C.R. Samanasi, S. Shit, D. Fernandes, R. Miriyala
Journal: Annals of Oncology (2024)
418P Updated results of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II study
Authors: Y. Guo, D.Z. Li, J. Lin, C. Sun, G. Cao, J. Wu, M. Ge, D. Hu, S. Qu, L. Shen, Y. Wei, J. Zong, M. Fang, C. Jin, Z-M. Li, Y. Sun, X. Wang, H. Zhang, W. Wang, Y. Zhu
Journal: Annals of Oncology (2024)
392P A single arm phase II study of single agent Pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Authors: S. Upadhya, S. Khurana, A. Kumar, P.S. Malik, R. Pramanik, B. Kataria, S. Mathur, M. Kumar, N. Bhatla, M. Ray
Journal: Annals of Oncology (2024)
397P Real-world outcome of dostarlimab in dMMR/MSI-H advanced/recurrent endometrial cancer: Updated results from Korean expanded access program
Authors: M.K. Kim, K. Kim, Y-Y. Lee, E.J. Nam, M.C. Lim, K.H. Kim, J.Y. Song, H.S. Kim, Y-S. Kwon, J. Bae, M.K. Kim, M.J. Bae
Journal: Annals of Oncology (2024)
403O Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
Authors: W.F. Fang, J. Pan, H. Wang, S. Qu, N. Chen, X. Chen, Y. Sun, X. He, C. Hu, L. Lin, C.J. Yen, Y. Wu, S. Yuan, C. Chen, Y. Yang, S. Leaw, L. Zhang
Journal: Annals of Oncology (2024)
479MO Erlotinib plus bevacizumab in patients with metastatic solid tumors with EGFR amplification: Results from the KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced solid tumors, KCSG AL 22-09)
Authors: J.W. Lee, Y-G. Lee, G-W. Lee, H.A. Jung, K-P. Kim, T-Y. Kim, H. Ryu, M.H. Ryu, M.S. Ahn, H. Yun, S. Ahn, H.S. Shim, J. Kim, J. Sim, S.Y. Kim, J.H. Kim, S. Lee
Journal: Annals of Oncology (2024)
LBA3 First-line HLX07 vs. placebo combined with serplulimab and chemotherapy for nasopharyngeal cancer: A randomised, double-blind, multicentre phase II study
Authors: L. Zhang, W.F. Fang, X. Ai, F. Lei, D. Ma, H. Ni, X. Hou, Q. Wang, H. Yu, J. Li
Journal: Annals of Oncology (2024)
502P A novel miRNA pair biomarker of miR-1180-3p|miR-505-3p for predicting neoadjuvant chemoradiotherapy survival in esophageal squamous cell carcinoma: A multicenter study in China
Authors: S.D. Xin, P. Wu, C. Zhang, W. Le, S. Nan, J. He
Journal: Annals of Oncology (2024)
524P A blood ctDNA multimodal-based assay for early detection of aggressive cancer types lacking standard screening tests
Authors: C.V.T. Nguyen, H.T-H. Nguyen, H.D. Vo, V.T.T. Van, N.A. Nguyen, L. Vu, H.T. Trung, T.N.N. Doan, H.T. Nguyen, L.S. Tran
Journal: Annals of Oncology (2024)
585P Representing the patterns of second primary cancers observed in Hospital Based Cancer Registry (HBCR) at Tata Memorial Centre, Mumbai
Authors: S.A. Cheulkar, A.S. Oak, K. Sivaranjini, E. Dashmukhe, M. Morajkar, A. Thakadiyil, P. Gode, V. Mishra, V. Chaurasia, P. Chaturvedi, R. Dikshit
Journal: Annals of Oncology (2024)
597P Adjuvant osimertinib in patients with completely resected, stage IB-IIIB NSCLC with uncommon EGFR mutations (ADMIN): Clinical characteristics, genomic profile and molecular residual disease
Authors: C. Liu, Y. Han, X. Leng, D. Yue, G. Zhao, C. Cheng, G. Li, N. Liang, J. Zhao, S. Liu, W. Huang, J. Wang, L. Liu
Journal: Annals of Oncology (2024)
LBA7 Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05
Authors: M-J. Ahn, J. Sands, A.E. Lisberg, L. Paz-Ares, E. Pons-Tostivint, M. Pérol, E. Felip, M.H. Hong, S. Sugawara, H. Hayashi, B.C. Cho, G. Blumenschein, E. Shum, Y. Goto, H. Zebger-Gong, K. Lakshminarayanan, D. Uema, I. Okamoto, W. Gu
Journal: Annals of Oncology (2024)
528MO Cognitive phenotypes and its association with role functioning outcomes in Adolescents and Young Adults (AYAs) with cancer
Authors: P. Xiao, Y. Wei, W. Deng, A.W.K. Leung, C.K. Ngan, H.H.F. Loong, C-K. Li, Y.T. Cheung
Journal: Annals of Oncology (2024)
439P Comparison of the efficacy and safety of neoadjuvant PD-1 inhibitors plus chemotherapy vs targeted therapy plus chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma (LA HPSCC)
Authors: Y. Zhang, W. Gao, L. Feng, X. Zhao, Z. Huang, D. Chen, G. Yin, W. Guo, Z. Huang
Journal: Annals of Oncology (2024)
441P Real-world data of nivolumab efficacy for treatment of recurrent or metastatic head and neck squamous cell carcinoma
Authors: M.V. Nosova, O. Stativko, E. Tsareva, I. Shangina, M. Ibragimova, E. Zueva, V. Latkin, M. Sobolev, O. Kuchevskaya, O. Arapova, E. Sabitov, T. Antonova, I. Pokataev, V.N. Galkin
Journal: Annals of Oncology (2024)
577P A real-world analysis of immune checkpoint inhibitors outcomes in patients with baseline auto-immune diseases
Authors: N.E. Omar, H. Elewa, M.O. Saad, M. Sir Elkhatim, A.R. Alnajjar, A. Gulied, A. Sahal, A. Asmar, F.E. Gebril, H.M. Afifi, M. Benkhadra, R. Dawoud, S. Elazzazy, A. Hamad
Journal: Annals of Oncology (2024)
435P Efficacy and toxicity of different adjuvant chemotherapy administration methods and regimens in locoregionally advanced nasopharyngeal carcinoma
Authors: J. Chen, H. Cheng, Y. Li, C.F. Tse, J.Y. Lin, P. Wang, B. Shen, H. Long, S. Liu, S-S. Guo, S. Liang, Q.Y. Chen, L.Q. Tang, H. Mai, L. Liu
Journal: Annals of Oncology (2024)
488P Audit of toxicity and tolerance of DPYD variant patients receiving fluoropyrimidines on effectiveness of recommended dose reductions in reducing toxicity
Authors: H.G.T. Brice, P.J.R. Teo, C. Goulden-Page, S. Kaur, A. Tew, H. Randev, S. Cruddas, J. Thompson, I. Geh
Journal: Annals of Oncology (2024)
445P Individualized neoadjuvant PD-1 inhibitors combined with chemotherapy for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): A single-center, retrospective trial
Authors: X. Chen, Z. Li, P. Li, H. Xu, Z. Yang, L. Li, J. Zhou, Y. Ding
Journal: Annals of Oncology (2024)
665P Real-world effectiveness and safety of first-line (1L) osimertinib for EGFR-mutated (EGFRm) advanced NSCLC: A prospective, multi-center, real-world study in China (FLOURISH Study)
Authors: J. Zhou, L. Shen, D. Lv, K. Tang, D. Zhu, Y. Zhao, K. Wang, Y. Wang, L. Xing, J. Cui, L. Ding, X. Shi, J. Zheng, J. Zhou
Journal: Annals of Oncology (2024)
LBA8 Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study
Authors: T. Mimori, T. Shukuya, Y. Goto, T. Asao, K. Takayama, K. Kaira, H. Tanaka, R. Ko, Y. Tsubata, M. Tachihara, T. Suzuki, J. Tanizaki, S. Sugawara, Y. Zenke, Y. Shirai, T. Hayashi, K. Mori, K. Takahashi
Journal: Annals of Oncology (2024)
630MO First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort
Authors: J.C-H. Yang, K. Kobayashi, B. Chewaskulyong, T.V. Tran, B. Biswas, K.H. Lee, P-H. Feng, X.D. Pham, Y. Yao, S. Kuyama, J.Y. Tan Chun Bing, R. Bhise, M-J. Ahn, V. Sriuranpong, R.K. Li, E. Armenteros Monterroso, K. Barrett, M. Albayaty, Y. Cheng
Journal: Annals of Oncology (2024)
484P Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1): second interim analysis
Authors: D. Halafyan, A. Stroganova, A. Bekyashev, A. Tryakin, D. Rogozhin, N. Kozlov, A. Petrovsky, S. Banov, A. Golanov, A. Mitrofanov, V. Aleshin, R. Sufianov, M. Byakhov, A. Savateev, I. Osinov, M. Nochnoy, N. Romanenko, A. Tsar, G.G. Makiev, I. Stilidi
Journal: Annals of Oncology (2024)
478O Updated results of oral PD-L1 inhibitor ABSK043 in advanced solid tumor patients (pts) from a phase I study
Authors: Y. Yu, A. Cooper, J. Coward, J. Zhang, Y. Shu, T. Zheng, J. Zhang, X. Du, J. Chen, X. Xu, Y. Li, S. Zhang, X. Wang, G. Zhang, Y. Chen, M. Zhang, T. Yi, R. An, X. Fang, S. Lu
Journal: Annals of Oncology (2024)
444P Comparative analysis of induction chemotherapy regimens for nasopharyngeal carcinoma: A retrospective single-center study
Authors: A. Alfagih, A.M.E. Mohammed, F. Hamadi, A.A. Alghamdi, A. Alshihre, H.M.H.M. Bakhribah, I.A. Algorashi, A.M. Al-Zahrani
Journal: Annals of Oncology (2024)
680P Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: An exploratory analysis of initial AFA dosage in Gio-Tag Japan, a multicenter prospective observational study
Authors: A. Hata, N. Takase, T. Sumi, H. Yoshioka, Y. Fujisaka, T. Ota, J. Osugi, M. Mitsui, R. Morita, S. Morita, K. Sakai, K. Nishio, N. Katakami
Journal: Annals of Oncology (2024)
504P Real-world prevalence of homologous recombination repair (HRR) gene mutations in advanced breast (ABC) and selected gastrointestinal cancers (GIC) using comprehensive next-generation sequencing (NGS) assays in Asia and the Middle East (AME)
Authors: V. Lavingia, N. Rohatgi, A. Bahl, M. Alakasheh, T-W. Huang, T.W. Ke, S. Dawood, N. Sandhir, S. Olsen
Journal: Annals of Oncology (2024)
485P High-sensitive multi-cancers early detection for 8 cancer types by cell-free DNA targeted methylation sequencing
Authors: H.Y. Luo, P. Li, W. Wei, Y-B. Lin, H. Yang, K. Luo, X. Zhong, X. Hu, H. Qiu, S. Yuan, X. Lin, B. Cui, Y. Li, R. Zhang, W. Fan, C. Lan, Y. Han, T. Wan, Q. Zhan, R-H. Xu
Journal: Annals of Oncology (2024)
523P Multimodal analysis of circulating tumor DNA (ctDNA) combining genetic and epigenetic alterations enhances assay sensitivity for multi-cancer early detection (MCED)
Authors: H.T-H. Nguyen, L.S. Tran, L. Vu, L. Tu, N.T. Tu, G.H. Vu, T.A. Nguyen, U. Tran, T. Do, H-N. Nguyen
Journal: Annals of Oncology (2024)
421P Induction chemotherapy and concurrent chemoradiotherapy with cisplatin for T4 nasoethmoidal squamous cell carcinoma: The value of paclitaxel, carboplatin and cetuximab (PCE)
Authors: N. Tanaka, T. Enokida, S. Okano, T. Fujisawa, R. Onaga, Y. Hoshi, H. Tanaka, A. Wada, M. Sato, N. Takeshita, T. Fujisawa, S. Zenda, M. Tahara
Journal: Annals of Oncology (2024)
398P Real-world data of PARP inhibitors in first-line maintenance for BRCA mutated or HRD positive advanced ovarian cancer: A multicenter retrospective study from India
Authors: Y.S. Kumar, S.S. Panda, L. Moharana, L. Samantaray, S.V. Saju, K.K. Rathnam, H.S. Raju, A. Sehrawat, D. Sundriyal, P.A. Kingsley, K.B. Priya, S. Kayal, B. Dubashi, A.O. Philips, S.L. Cyriac, S. Natarajan, S.S. Mohanty, P. Ganesan
Journal: Annals of Oncology (2024)
401TiP Adebrelimab plus chemotherapy and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab in platinum-sensitive relapsed ovarian cancer (CHANGCHUN): A single-arm, exploratory study
Authors: Z. Liu, C. Chen, X. Cong, Y. Zhu, Z. Liu
Journal: Annals of Oncology (2024)
508P Survival outcomes of patients with tropomyosin receptor kinase fusion-positive cancer receiving larotrectinib versus standard of care: a matching-adjusted indirect comparison using real-world data
Authors: C. Bokemeyer, K. Abrams, J. Garcia-Foncillas, A. Italiano, U.N. Lassen, L. Linsell, M. Marian, N. Paracha, S. Sullivan, J. Thompson
Journal: Annals of Oncology (2024)
462TiP GRASSROOT: Global real-world data in patients with advanced thyroid cancer on standard of care and specialized interventions - Registry of oncologic outcomes with testing and treatment
Authors: P.C. Iyer, J. Wang, R. Dadu, M. Zafereo, A. Maniakas, S. Hamidi, N. Busaidy, R. Ferrarotto, L. de Sousa, V. Banuchi, B. Gunn, M. Spiotto, N. Akhave, M.E. Cabanillas
Journal: Annals of Oncology (2024)
405O Accuracy of plasma Epstein-Barr virus (EBV) DNA for disease surveillance in endemic nasopharyngeal carcinoma (NPC): Analysis of a real-world database (RWD)
Authors: W.M.M. Chow, J. Neo, E. Ong, J. Wee, K.W. Fong, Y.L. Soong, T. Tan, J. Tan, S.Y. Sin, J. Liu, K.S. Loh, J.K. Tay, M-K. Ang, S.H. Tan, D.W-T. Lim, M.L.K. Chua
Journal: Annals of Oncology (2024)
410MO Pattern and treatment outcomes of second primary cancer (SPC) of the upper aerodigestive tract (UADT) in head and neck squamous cell carcinoma (HNSCC) survivors: A multi-center retrospective cohort study with long-term follow-up
Authors: J.C.K. Yung, J.C-H. Chow, K.M. Cheung, K.K.H. Bao, C.K. Kwan, H.H.Y. Yiu
Journal: Annals of Oncology (2024)
451P Identification of a biomarker compendium for different clinical stages of oral submucous fibrosis by second gel electrophoresis and mass spectrometry along with validations: A first Indian experience
Authors: Y. Madhavan, D. Catakapatri Venugopal, V. Shyamsundar, S. Sairaman, A. Krishnamurthy, V. Ramshankar
Journal: Annals of Oncology (2024)
400TiP An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
Authors: J-Y. Lee, V. Makker, A. Oaknin, D-Y. Oh, C. Anoka, L. Jung, J. Simões, S.D. Puvvada, F. Meric-Bernstam
Journal: Annals of Oncology (2024)
413MO Impacts of time-of-day of nivolumab infusion on treatment efficacy for patients with head and neck squamous cell carcinoma
Authors: T. Tsunoki, S. Kadowaki, T. Mizuno, Y. Ishizuka, T. Sakakida, Y. Narita, K. Honda, T. Masuishi, H. Taniguchi, M. Ando, K. Muro, N. Hanai
Journal: Annals of Oncology (2024)
402O Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)
Authors: R-H. Xu, D. Ruan, F. Han, Y. Zhou, F. Wang, L.Q. Tang, Z. Li, C. Chen, J. Lin, F. Liu, F. Xiao, Y. Shi
Journal: Annals of Oncology (2024)
388P RENI-1 efficacy and safety of niraparib as first-line maintenance therapy in newly diagnosed ovarian cancer: A prospective, multicenter real-world study, updated in 24-month follow-up
Authors: Z. Zheng, J. Zuo, K. Wang, C. Zhumei, Q. Li, C. Xiaodong, L.X. Sun, Z. Hui, J. Zhang, S. Wang, D. Cao, L. Chen, H. Zhao, W. Duan, M. Zheng, H. Shou, J. Li, Y. Wang, L. Wu
Journal: Annals of Oncology (2024)
440P Low-dose nivolumab six weekly plus triple metronomic chemotherapy in advanced head and neck cancer: A prospective, open label single centre study from eastern India
Authors: S.K. Swain, L. Moharana, A. Dubey, R. Singhal, A. Sanyal, G. Biswas, I. Bhavya, L. Samantaray, A. Bhange, A. Mahajan, P.R. Sahoo, S.S. Panda
Journal: Annals of Oncology (2024)
406MO Unique molecular features of Epstein Barr virus-specific cytotoxic T lymphocyte (EBV-CTL) as biomarkers for advanced nasopharyngeal cancer (NPC) patients who received chemotherapy and EBV-CTL
Authors: T.W.H. Shuen, R. Ba, A. Liu, Y.L. Charmaine Tan, L.S. Koh, Y.H. Joelle Chua, R. Cheong, S.K. Hew, C.L. Chee, C.W. Janice Lim, A. Chu, S. Han, P. Wang, H.C. Toh
Journal: Annals of Oncology (2024)
447P Evaluating the efficacy and safety of pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter, retrospective study analysis
Authors: M. Hu, C. Chen, Y. Wang, S. Zhang, Y. Han, H. Wu, J. Gao, H. Wu, Q. Lin, W. Shang, X. Li, H. Feng, Q. Qiao, G. Hu, K. Yang, X. Song, D. Cao, M. Kang, R. Wang, J. Yu
Journal: Annals of Oncology (2024)
407MO Capecitabine combined with PD-1 antibody as maintenance therapy after first-line treatment of recurrent or metastatic nasopharyngeal carcinoma: A propensity score matching study
Authors: Y. Li, Y. Chen, H. Cheng, J. Shen, B. Shen, H. Long, X-S. Sun, J. Chen, J. Peng, P. Wang, S-S. Guo, Q.Y. Chen, L.Q. Tang, H. Mai, L. Liu
Journal: Annals of Oncology (2024)
521P Real-world performance of a comprehensive next-generation sequencing (NGS) assay for solid tumor patients in Asia and the Middle East (AME)
Authors: N. Rohatgi, C-M. Tsai, A. Bahl, A. Rauthan, A. Agarwal, S. Dawood, M. Alakasheh, A. Kaur, N. Sandhir, S. Olsen
Journal: Annals of Oncology (2024)
498P Predictive modeling of oncogenic RNA expression using DNA alterations: Insights from Asian rare cancer patients
Authors: K.Y. de Almeida, H.S. Okuma, M.S. Imasa, P-J. Voon, S.H. Hwoei Fen, T.W-W. Chen, S. Yusak, R. Ramachandran, N. Abu Bakar, M-H. Chen, K. Nakamura, K. Yonemori
Journal: Annals of Oncology (2024)
412MO A real-world phase IV superiority study among recurrent or advanced head and neck cancer patients prescribed with low-dose nivolumab and triple metronomic chemotherapy versus paclitaxel carboplatin regimen
Authors: A.D. Khadela, R. Parikh, J. Vaghela, Y. Chauhan, R.K. Kothari, M. Patel
Journal: Annals of Oncology (2024)
369P Experience with triplet therapy in denovo metastatic hormone sensitive prostate cancer: Single center from India
Authors: V. Panicker, S. Roy, D. Dabkara, B. Biswas, A. Bhattacharjee, S. Bhattacharjee, S. Gupta, I. Mallick, D. Midha, S. Mukhopadhyay, Y.S. Patel, H.M. Patel, R. Mahishi
Journal: Annals of Oncology (2024)
316P Deciphering the poor prognostic signature of SLC7A5 in clear cell renal cell carcinoma and its impact on tumor immune microenvironment
Authors: R.K. Jadallah, M.Z. Al-Bataineh, L.E. Obeidat, T.H. Rawashdeh, A.H. Al Sharie
Journal: Annals of Oncology (2024)
325P Application of extended immunotherapy in advanced clear cell renal cell carcinoma treated with first-line combination of immune-checkpoint inhibitor and tyrosine kinase inhibitor
Authors: Q. Wang, X. Zhang, Q. Zhu, H. Zeng, J. Chen, J. Zhao, J. Dai, G. Sun, Z. Liu, H. Zeng, P. Shen
Journal: Annals of Oncology (2024)